Burning Rock Biotech (BNR) Leases (2021 - 2023)

Burning Rock Biotech has reported Leases over the past 3 years, most recently at $1.7 million for Q4 2023.

  • Quarterly results put Leases at $1.7 million for Q4 2023, down 74.83% from a year ago — trailing twelve months through Dec 2023 was $1.7 million (down 74.83% YoY), and the annual figure for FY2023 was $1.7 million, down 75.9%.
  • Leases for Q4 2023 was $1.7 million at Burning Rock Biotech, down from $6.8 million in the prior quarter.
  • Over the last five years, Leases for BNR hit a ceiling of $12.7 million in Q4 2021 and a floor of $1.7 million in Q4 2023.
  • Median Leases over the past 3 years was $6.8 million (2022), compared with a mean of $7.1 million.
  • Biggest five-year swings in Leases: crashed 46.51% in 2022 and later tumbled 74.83% in 2023.
  • Burning Rock Biotech's Leases stood at $12.7 million in 2021, then crashed by 46.51% to $6.8 million in 2022, then tumbled by 74.83% to $1.7 million in 2023.
  • The last three reported values for Leases were $1.7 million (Q4 2023), $6.8 million (Q4 2022), and $12.7 million (Q4 2021) per Business Quant data.